Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase

Journal of Medicinal Chemistry

Volumn 48, Issue 14, 2005, Pages 4547-4557

  Harper, Steven ^a   Avolio, Salvatore ^a   Pacini, Barbara ^a   Di Filippo, Marcello ^a   Altamura, Sergio ^a   Tomei, Licia ^a   Paonessa, Giacomo ^a   Di Marco, Stefania ^a   Carfi, Andrea ^a   Giuliano, Claudio ^a   Padron, Julio ^a   Bonelli, Fabio ^a   Migliaccio, Giovanni ^a   De Francesco, Raffaele ^a   Laufer, Ralph ^a   Rowley, Michael ^a   Narjes, Frank ^a  

^a IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 CARBOXY 3 CYCLOHEXYL 2 (4 METHOXYPHENYL) 1H INDOL 1 YL]ACETYL] N,N DIETHYLPIPERIDIN 4 AMMONIUM CHLORIDE; ACETAMIDE DERIVATIVE; CILUPREVIR; ENZYME INHIBITOR; INDOLE DERIVATIVE; INDOLE N ACETAMIDE DERIVATIVE; PREGNANE X RECEPTOR; RNA POLYMERASE; RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOG; DRUG BIOAVAILABILITY; DRUG HALF LIFE; HEPATITIS C VIRUS; IC 50; MALE; NONHUMAN; PLASMA CLEARANCE; RAT; RECEPTOR UPREGULATION; RNA REPLICATION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ACETAMIDES; ALLOSTERIC REGULATION; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; DOGS; GENOME, VIRAL; HALF-LIFE; HEPACIVIRUS; HUMANS; INDOLES; MODELS, MOLECULAR; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA REPLICASE; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 22244435560     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050056+     Document Type: Article

References (25)

1. Choo, Q.-L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA Clone Derived from a Blood-borne Non-A, Non-B Viral Hepatitis Genome. Science 1989, 244, 359-362.
2. Sarbah, S. A.; Younossi, Z. M. Hepatitis C: An Update on the Silent Epidemic. J. Clin. Gastroenterol. 2000, 30, 125-143.
3. NIH Consensus Statements. Management of Hepatitis C; National Institutes of Health: Bethesda, MD, 2002; Vol. 19, Issue 1.
4. Dymock, B. W. Emerging Therapies for Hepatitis C Virus Infection. Emerging Drugs 2001, 6, 13-42.
5. Lohmann, V.; Korner, F.; Koch, J.; Henan, U.; Theilmann, L.; Bartenschlager, R. Replication of Subgenomic Hepatitis C Virus RNA's in a Hepatoma Cell Line. Science 1999, 285, 110-113.
6. Tan, S.-L.; Victor, F.; Chen, S.-H. HCV Protease Inhibitors as Potential Therapeutic Agents for the Treatment of HCV Infection. Front. Biotechnol. Pharm. 2004, 4 123-146.
7. Hinrichsen, H.; Benhamou, Y.; Wedemeyer, H.; Reiser, M.; Sentjens, R. E.; Calleja, J. L.; Forns, X.; Erhardt, A.; Cronlein, J.; Chaves, R.; Yong, C.-L.; Nehmiz, G.; Steinmann, G. G. Short-Term Antiviral Efficacy of BILN 2061, a HCV Serine Protease Inhibitor, in Hepatitis C Genotype 1 Patients. Gastroenterology 2004, 127, 1347-1355.
8. Beaulieu, P. L.; Tsantrizos, Y. S. Inhibitors of the HCV NS5B Polymerase: New Hope for the Treatment of Hepatitis C Infections. Curr. Opin. Invest. Drugs 2004, 5, 838-850.
9. Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal Structure of the RNA-Dependent RNA Polymerase from Hepatitis C Virus Reveals a Fully Encircled Active Site. Nat. Struct. Biol. 1999, 6, 937-943.
10. LaPlante, S.; Jakalian, A.; Aubry, N.; Bousquet, Y.; Ferland, J.-M.; Gillard, J.; Lefebvre, S.; Poirier, M.; Tsantrizos, Y. S.; Kukolj, G.; Beaulieu, P. L. Drug Design: Binding Mode Determination of Benzimidazole Inhibitors of the Hepatitis C Virus RNA Polymerase by a Structure and Dynamics Strategy. Angew. Chem., Int. Ed. 2004, 43, 4306-4311.
11. Carroll, S. S.; Tomassini, J. E.; Bosserman, M.; Getty, K.; Stahlhut, M. W.; Eldrup, A. B.; Bhat, B.; Hall, D.; Simcoe, A. L.; LaFemina, R.; Rutkowski, C. A.; Bohdan, W.; Yang, Z.; Migliaccio, G.; De Francesco, R.; Kuo, L. C.; MacCoss, M.; Olsen, D. B. Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs. J. Biol. Chem. 2003, 278, 11979-11984.
12. Dhanak, D.; Duffy, K. J.; Johnston, V. K.; Lin-Goerke, J.; Darcy, M.; Shaw, A. N.; Gu, B.; Silverman, C.; Gates, A. T.; Nonnemacher, M. R.; Earnshaw, D. L.; Casper, D. J.; Kaura, A.; Baker, A.; Greenwood, C.; Gutshall, L. L.; Maley, D.; DelVecchio, A.; Macarron, R.; Hofmann, G. A.; Alnoah, Z.; Cheng, H.-Y.; Chan, G.; Khandekar, S.; Keenan, R. M.; Sarisky, R. T. Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase. J. Biol. Chem. 2002, 277, 38322-38327.
13. (a) Chan, L.; Das, S. K.; Reddy, T. J.; Poisson, C.; Proulx, M.; Pereira, O.; Courchesne, M.; Roy, C.; Wang, W.; Siddiqui, A.; Yannopoulos, C. G.; Nguyen-Ba, N.; Labrecque, D.; Bethell, R.; Hamel, M.; Courtemanche-Asselin, P.; L'Heureux, L.; David, M.; Nicolas, O.; Brunette, S.; Bilimoria, D.; Bedard, J. Discovery of Thiophene-2-carboxylic Acids as Potent Inhibitors of HCV NS5B Polymerase and HCV Subgenomic RNA Replication. Part 1: Sulfonamides. Bioorg. Med. Chem. Lett. 2004, 14, 793-796.
14. (b) Chan, L.; Pereira, O.; Reddy, T. J.; Das, S. K.; Poisson, C.; Courchesne, M.; Proulx, M.; Siddiqui, A.; Yannopoulos, C. G.; Nguyen-Ba, N.; Roy, C.; Nasturica, D.; Moinet, C.; Bethell, R.; Hamel, M.; L'Heureux, L.; David, M.; Nicolas, O.; Courtemanche-Asselin, P.; Brunette, S.; Bilimoria, D.; Bedard, J. Discovery of Thiophene-2-carboxylic Acids as Potent Inhibitors of HCV NS5B Polymerase and HCV Subgenomic RNA Replication. Part 2: Tertiary Amides. Bioorg. Med. Chem. Lett. 2004, 14, 797-800.
15. Beaulieu, P. L.; Bousquet, Y.; Gauthier, J.; Gillard, J.; Marquis, M.; McKercher, G.; Pellerin, C.; Valois, S.; Kukolj, G. Non-Nucleoside Benzimidazole-Based Allosteric Inhibitors of the Hepatitis C Virus NS5B Polymerase: Inhibition of Subgenomic Hepatitis C Virus RNA Replicons in Huh-7 Cells. J. Med. Chem. 2004, 47, 6884-6892.
16. Harper, S.; Pacini, B.; Avolio, S.; Di Filippo, M.; Migliaccio, G.; Laufer, R.; De Francesco, R.; Rowley, M.; Narjes, F. Development and Preliminary Optimization of Indole-N-Acetamide Inhibitors of Hepatitis C Virus NS5B Polymerase. J. Med. Chem. 2005, 48, 1314-1317.
17. (a) Tomei, L.; Altamura, S.; Bartholomew, L.; Biroccio, A.; Ceccacci, A.; Pacini, L.; Narjes, F.; Gennari, N.; Bisbocci, M.; Incitti, I.; Orsatti, L.; Harper, S.; Stansfield, L; Rowley, M.; De Francesco, R.; Migliaccio, G. Mechanism of Action and Antiviral Activity of Benzimidazole-Based Allosteric Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase. J. Virol. 2003, 77, 13225-13231.
18. (b) McKercher, G.; Beaulieu, P. L.; Lamarre, D.; LaPlante, S.; Lefebvre, S.; Pellerin, C.; Thauvette, L.; Kukolj, G. Specific Inhibitors of HCV Polymerase Identified Using an NS5B with Lower Affinity for Template/Primer Substrate. Nucleic Acids Res. 2004, 32, 422-431.
19. (a) El-Sankary, W.; Gibson, G. G.; Ayrton, A.; Plant, N. Use of a Reporter Gene Assay To Predict and Rank the Potency and Efficacy of CYP3A4 Inducers. Drug Metab. Dispos. 2001, 29 1499-1504.
20. (b) Ogg, M. S.; Williams, J. M.; Tarbit, M.; Goldfarb, P. S.; Gray, T. J.; Gibson, G. G. A Human Reporter Gene Assay To Assess the Molecular Mechanisms of Xenobiotic-Dependent Induction of the Human CYP3A4 Gene in-Vitro. Xenobiotica 1999, 29, 269-279.
21. Full details on the binding mode and mechanism of action of 1 when bound to the NS5B enzyme will be published elsewhere. DiMarco, S.; Volpari, C.; Tomei, L.; Altamura, S.; Harper, S.; Narjes, F.; Koch, U.; Rowley, M.; De Francesco, R.; Migliaccio, G.; Carfi, A. Interdomain Communication in NS5B HCV Polymerase Abolished by Small-Molecule Inhibitors Bound to a Novel Allosteric Site. Manuscript submitted.
22. Rodgers, J. D.; Lam, P. Y. S.; Johnson, B. L.; Wang, H.; Ko, S. S.; Seitz, S. P.; Trainor, G. L.; Anderson, P. S.; Klabe, R. M.; Bacheler, L. T.; Cordova, B.; Garber, S.; Reid, C.; Wright, M. R.; Chang, C.-H.; Erickson-Viitanen, S. Design and Selection of DMP 850 and DMP 851: The Next Generation of Cyclic Urea HIV Protease Inhibitors. Chem. Biol. 1998, 5, 597-608 and references therein.
23. Goodwin, B.; Redinbo, M. R.; Kliewer, S. A. Regulation of CYP3A Gene Transcription by the Pregnane X Receptor. Ann. Rev. Pharmacol. Toxicol. 2002, 42 1-23.
24. MDS Pharma Services Taiwan Ltd., Pharmacology Laboratories, 158 Li-The Road, Peitou, Taipei, Taiwan 112, R.O.C.
25. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Boes, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; St. George, R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C.-L.; Llinas-Brunet, M. An NS3 Protease Inhibitor with Antiviral Effects in Humans Infected with Hepatitis C Virus. Nature 2003, 426, 186-189.